Less than four months after it recalled 155,000 bottles of tainted eye solution from its plant in Gujarat, India, Sun Pharmaceutical Industries says it is taking steps to streamline and standardize its manufacturing. With 23 plants on four continents, the changes will keep things from getting lost in translation for the Indian genericsmaker.
"We are looking at how to ensure the same practices and processes [across manufacturing facilities]," Sun Pharma Managing Director Dilip Shanghvi told The Hindu Business Line.
In order to streamline production and improve efficacy, the Indian generics giant will revamp its manufacturing practices to improve manufacturing time and lessen mistakes. To make sure that goes smoothly, Sun Pharma says it will add a global technical head with relative experience in overseeing daily operations.
The company experienced a number of GMP shortcomings at some of its U.S. facilities in recent years, including a consent decree for its subsidiary Caraco Pharmaceutical Laboratories. In March, Sun Pharma recalled its eye solution for conjunctivitis after regulators discovered impurities, according to an FDA inspection report. Sun said it had identified the causes of the problem and taken corrective action.
The changes come as Sun continues its back and forth with genericsmaker Taro Pharmaceutical Industries. Taro last week rejected as "inadequate" Sun's $367 million bid to buy the one-third of the company it doesn't currently own.
- learn more from The Hindu Business Line